CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,606,725 | +112.4% | 154,900 | +28.7% | 0.00% | – |
| Q2 2023 | $2,169,139 | -23.5% | 120,374 | -31.8% | 0.00% | – |
| Q1 2023 | $2,834,156 | +24.8% | 176,473 | +42.2% | 0.00% | – |
| Q4 2022 | $2,270,426 | +94.4% | 124,067 | +108.7% | 0.00% | – |
| Q3 2022 | $1,168,000 | +15.3% | 59,457 | +9.5% | 0.00% | – |
| Q2 2022 | $1,013,000 | -52.9% | 54,286 | -44.6% | 0.00% | – |
| Q1 2022 | $2,150,000 | +11.1% | 97,934 | +43.8% | 0.00% | – |
| Q4 2021 | $1,935,000 | +689.8% | 68,097 | +485.9% | 0.00% | – |
| Q3 2021 | $245,000 | -0.8% | 11,622 | -11.3% | 0.00% | – |
| Q2 2021 | $247,000 | +31.4% | 13,109 | +6.4% | 0.00% | – |
| Q1 2021 | $188,000 | -30.9% | 12,320 | -36.2% | 0.00% | – |
| Q4 2020 | $272,000 | -14.5% | 19,320 | -4.9% | 0.00% | – |
| Q3 2020 | $318,000 | -12.9% | 20,320 | -2.5% | 0.00% | – |
| Q2 2020 | $365,000 | +162.6% | 20,834 | +120.8% | 0.00% | – |
| Q1 2020 | $139,000 | -57.4% | 9,436 | -27.4% | 0.00% | – |
| Q4 2019 | $326,000 | +91.8% | 12,998 | +14.9% | 0.00% | – |
| Q3 2019 | $170,000 | -46.2% | 11,308 | -10.3% | 0.00% | – |
| Q2 2019 | $316,000 | -53.7% | 12,613 | -57.9% | 0.00% | – |
| Q1 2019 | $682,000 | +281.0% | 29,944 | +404.8% | 0.00% | – |
| Q4 2018 | $179,000 | +397.2% | 5,932 | +377.2% | 0.00% | – |
| Q3 2018 | $36,000 | – | 1,243 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |